Dongguan HEC Medicine Development

Dongguan HEC Medicine Development is the core research and development subsidiary of HEC Pharm, a leading Chinese pharmaceutical company. The company focuses on the discovery and development of innovative drugs across several therapeutic areas, including infectious diseases, metabolic disorders, and oncology. HEC Pharm is well-known for its dominant market position in the anti-influenza segment with its oseltamivir product, Kewei. The R&D pipeline includes a mix of generic improvements and novel chemical entities, with a significant emphasis on small molecule inhibitors and biologics. The company operates one of the largest private pharmaceutical R&D centers in China, located in Dongguan, and maintains a vertically integrated model from drug discovery to large-scale manufacturing.